CDR2

Across TCGA pan-cancer cohorts, CDR2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDR2 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CDR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDR2 expression acts as an unfavorable survival marker.

OV, PAAD, and UCEC are the cancer types where CDR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.361	0.842	.004	18	view →
PAAD	DFS	Median	All	0.100	0.484	.003	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CDR2–OV (OS)

Open the OV breakdown →